Effectiveness of lifestyle interventions in NALFD (non-alcoholic fatty liver disease) - how are clinical trials affected?

Effectiveness of lifestyle interventions in NALFD (non-alcoholic fatty liver disease) - how are clinical trials affected? Expert Opin Investig Drugs. 2020 Jan 14;: Authors: Michel M, Schattenberg JM PMID: 31933385 [PubMed - as supplied by publisher]
Source: Expert Opinion on Investigational Drugs - Category: Drugs & Pharmacology Tags: Expert Opin Investig Drugs Source Type: research

Related Links:

Authors: El Sherif O, Dhaliwal A, Newsome PN, Armstrong M Abstract Introduction: Sarcopenia is increasingly recognised in patients with non-alcoholic liver disease (NAFLD). Initially recognised as a consequence of advanced liver disease, there is now emerging evidence that sarcopenia may be a novel risk factor for the development of NAFLD, with a role in fibrosis and disease progression.Areas covered: This review examines the epidemiology, pathogenesis and complex interplay between NAFLD and sarcopenia. Furthermore, the authors discuss the challenges with diagnosis of sarcopenia in the clinic and the evidence-based...
Source: Expert Review of Gastroenterology and Hepatology - Category: Gastroenterology Tags: Expert Rev Gastroenterol Hepatol Source Type: research
CONCLUSIONS: Based on these results, 8.1% of Mexican general population without a history of liver disease is at high risk of having advanced liver fibrosis and complications and death derived from cardiovascular disease and cirrhosis. Most of them showed normal ALT serum levels. PMID: 32063504 [PubMed - as supplied by publisher]
Source: Annals of Hepatology - Category: Gastroenterology Tags: Ann Hepatol Source Type: research
Authors: Meunier L, Larrey D Abstract Some drugs may induce hepatotoxic lesions, such as steatosis or steatohepatitis found in Non-Alcoholic Fatty Liver Disease (NAFLD). Among these drugs there are some anti-tumoral molecules, such as methotrexate, 5-fluorouracil, irinotecan, tamoxifen and l-asparaginase. The hepatotoxic phenotype developed from treatment with such drugs is known as "CASH" for "Chemotherapy-induced Acute Steatohepatitis". The mechanism of toxicity is essentially based on mitochondrial toxicity. These lesions are chronic and often reversible when the treatment is stopped. Contrib...
Source: Annals of Hepatology - Category: Gastroenterology Tags: Ann Hepatol Source Type: research
Publication date: Available online 17 February 2020Source: MitochondrionAuthor(s): Pallavi Shukla, Srabani MukherjeeAbstractPolycystic ovary syndrome (PCOS) is a common endocrine disorder characterized by irregular menstrual cycles, hyperandrogenism and subfertility. Due to its complex manifestation, the pathogenic mechanism of PCOS is not well defined. Cumulative effect of altered genetic and epigenetic factors along with environmental factors may play a role in the manifestation of PCOS leading to systemic malfunction. With failure of genome-wide association study (GWAS) and other studies performed on nuclear genome to p...
Source: Mitochondrion - Category: Biochemistry Source Type: research
Contributors : Yan Liu ; Liangyou RuiSeries Type : Expression profiling by arrayOrganism : Mus musculusLiver steatosis is a driving force for nonalcoholic fatty liver disease (NAFLD), alcoholic liver disease, insulin resistance, and type 2 diabetes. Slug (also called Snai2 or Snail2) is a transcriptional regulator that may play a critical role in the regulation of liver function.To prove that, we used microarrays to detail the hepatic Slug regulated gene expression underlying liver steatosis and identified distinct pathways controlled by Slug during this process.
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by array Mus musculus Source Type: research
This study aimed to investigate whether microRNAs mediated the pathoge...
Source: BMC Gastroenterology - Category: Gastroenterology Authors: Tags: Research article Source Type: research
Following publication of the original article [1], we have been notified that the given name of one of the authors was spelled incorrectly.
Source: BMC Gastroenterology - Category: Gastroenterology Authors: Tags: Correction Source Type: research
Semin Liver Dis DOI: 10.1055/s-0040-1701443Alcohol and obesity are the main risk factors for alcoholic liver disease and nonalcoholic fatty liver disease (NAFLD), respectively, and they frequently coexist. There are considerable synergistic interaction effects between hazardous alcohol use and obesity-associated metabolic abnormalities in the development and progression of fatty liver disease. Intermittent binge-drinking has been shown to promote steatohepatitis from obesity-related steatosis, and binge-drinking is associated with progression to cirrhosis even when average alcohol intake is within the currently used criter...
Source: Seminars in Liver Disease - Category: Gastroenterology Authors: Tags: Review Article Source Type: research
AbstractAimMediterranean diet (MD) is a healthful dietary pattern with benefits for prevention of metabolic diseases including non-alcoholic fatty liver disease (NAFLD). In the current meta-analysis, we assessed the association between MD and liver steatosis and cardiometabolic risk factors in patients with NAFLD.MethodsPubMed, Scopus, and Embase were searched to find observational and clinical studies on the issue. No restriction on date and language was made. Outcomes included body mass index (BMI), waist circumference, blood pressure, triglycerides (TG), cholesterol fractions, glucose, insulin, insulin resistance, and l...
Source: Journal of Diabetes and Metabolic Disorders - Category: Endocrinology Source Type: research
AbstractSilymarin, an extract from milk thistle seeds, has been used for centuries to treat hepatic conditions. Preclinical data indicate that silymarin can reduce oxidative stress and consequent cytotoxicity, thereby protecting intact liver cells or cells not yet irreversibly damaged. Eurosil 85® is a proprietary formulation developed to maximize the oral bioavailability of silymarin. Most of the clinical research on silymarin has used this formulation. Silymarin acts as a free radical scavenger and modulates enzymes associated with the development of cellular damage, fibrosis and cirrhosis. These hepatoprotective eff...
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
More News: Alcoholism | Clinical Trials | Drugs & Pharmacology | Fatty Liver Disease (FLD) | Liver | Liver Disease | Non-alcoholic Fatty Liver Diseases (NAFLD) | Urology & Nephrology